Tyrosinase peptide antigens (TYR peptides)

Tyrosinase peptide antigens are specific amino acid sequences derived from the tyrosinase enzyme (EC 1.14.18.1), which serves as the primary catalyst for melanin production in melanocytes (Source: UniProt P14679). These peptides are processed intracellularly and presented by Major Histocompatibility Complex (MHC) molecules, such as HLA-A*02:01, allowing them to be recognized by cytotoxic T lymphocytes (Source: PubMed PMID: 7513007). Because tyrosinase is overexpressed in the majority of malignant melanomas, these peptides are utilized as targets for cancer immunotherapies, including peptide-based vaccines and TCR-engineered T-cell therapies (Source: National Cancer Institute). Clinical trials have demonstrated that targeting these antigens can induce tumor regression, although it often results in vitiligo due to the destruction of normal melanocytes (Source: PubMed PMID: 15150569). The most commonly studied epitope is the tyrosinase 368-376 peptide, which is frequently modified in therapeutic settings to enhance its MHC binding affinity and immunogenicity (Source: PubMed PMID: 9544471).

Other names

Tyrosinase-derived peptidesMelanoma-associated antigen tyrosinaseTYR epitopesTyrosinase-related antigensTyrosinase-derived epitopes

Induction of antigen-specific cytotoxic T lymphocyte (CTL) responses against cells expressing the tyrosinase protein, leading to targeted cell lysis.